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S U M M A R Y
Objectives: Mitochondrial toxicity is an important toxicity of antiretroviral therapy and may manifest as
elevated blood lactate. Macrocytosis has been hypothesized to act as a marker of mitochondrial toxicity
in persons with HIV infection. As part of a larger study on markers of mitochondrial toxicity we evaluated
the relationship between resting lactate and erythrocyte mean corpuscular volume (MCV).
Methods: We studied the effect of micronutrient supplementation on lactate metabolism in three
groups: those with HIV on and not on dideoxynucleoside-containing antiretroviral therapy and those
without HIV. As part of the study we measured resting lactate and erythrocyte MCV after a 14-h fast.
Results: Erythrocyte MCV was signiﬁcantly higher among the 11 participants on antiviral therapy (109.3
femtoliters (ﬂ)) compared to ﬁve controls without HIV (89.3 ﬂ) and four controls with HIV not on
antiviral therapy (88.3 ﬂ). In addition a strong predictive relationship was seen between MCV and resting
lactate (R2 = 0.548, p < 0.01).
Conclusions: Macrocytosis may be a marker of treatment-related mitochondrial dysfunction in persons
on treatment for HIV. Evaluating patients for early evidence of mitochondrial dysfunction in resource-
constrained settings could be facilitated by this marker.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Macrocytosis is a well recognized complication of zidovudine
(AZT) therapy, in which setting it may accompany severe,
treatment-limiting anemia. Indeed the presence of macrocytosis
can be used as an indicator of adherence with AZT.1 Other
nucleoside analogs are less likely to result in an elevation in mean
corpuscular volume (MCV),2 with relatively little in the literature
outside of three papers on stavudine (D4T).3–5 Spooner et al.
concluded in their letter published in 1999 that macrocytosis
associated with D4T does not warrant further investigation.5
The mechanism by which red blood cells increase in size
appears to be related to DNA biosynthetic changes 30 and changes
in erythrocyte plasma membrane cholesterol and fatty acid
balance.6,7 The observation that macrocytosis may represent a
manifestation of mitochondrial dysfunction has only recently been
made.8
Other conditions known to be associated with macrocytosis
include deﬁciencies of vitamin B12 and folate, liver disease,§ Presented at the 11th International Workshop on Adverse Drug Reactions and
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agents that are known to cause macrocytosis include alcohol
(dose-related), sunitinib, imatinib, valproic acid, hydroxycarba-
mide, and other antineoplastic agents.9 Macrocytosis in heavy
drinkers has been associated with an increased risk of esophageal
cancer.10
Red blood cells appear to contribute to the amelioration of
oxidative stress through a number of mechanisms including low
molecular weight antioxidants of the cell membrane and its ability
to regenerate consumed redox equivalents.11 Indeed, the presence
of macrocytosis may be a readily measurable marker of
mitochondrial dysfunction as suggested by a strong relationship
between MCV and the methionine breath test, a marker of hepatic
mitochondrial dysfunction.8
2. Methods
We sought to study the effects on lactate metabolism of HIV
infection and its treatment, as well as a 6-week course of
supplementation with thiamine, riboﬂavin, and L-carnitine
(NCT00202228, http://www.clinicaltrials.gov). The study was
conducted between 2002 and 2007 and targeted for enrollment
those persons on dideoxynucleoside antiviral agents. Three groups
were analyzed: group 1 consisted of HIV-positive patients not on
antiviral therapy (n = 4), group 2 consisted of HIV-positive patientsses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Fasting lactate versus mean corpuscular volume.
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patients (n = 5). Resting venous lactate was measured after a 12-h
fast with a Beckman Coulter Unicell DXC. MCV was estimated using
a Sysmex XE-HST analyzer. The normal range for lactate in our
laboratory is 0.5–2.2 mmol/l and for MCV is 81–98 femtoliters (ﬂ).
Lactate production was estimated using the method proposed by
Connor et al.,12 using a weight standardized lactate infusion
challenge. With an assumption of steady-state kinetics, lactate
production was estimated using the area under the curve of serum
lactate levels during and after the lactate infusion. Linear variables
were analyzed by one-way analysis of variance (ANOVA) and linear
regression using SPSS v.16.0 (IBM Corp., Somers, NY, USA).
Ethical approval was obtained from the Ethics Review Board of
Queen’s University, Kingston, Canada.
3. Results
Those on HIV treatment (group 2) were predominantly male
(10/11; 91%), whereas groups 1 and 3 had 2/4 and 2/5 males,
respectively. Mean age was 38.5 years in group 1, 45.5 years in
group 2, and 30.6 years in group 3. For those with HIV, the time
since diagnosis was 9 years for group 1 and 13 years for group 2.
The group on treatment was highly treatment experienced with a
mean duration of treatment of 9.4 years (range 1–14 years).
Higher fasting lactate was found among those in group 2 (1.8
mmol/l) vs. group 1 (0.9 mmol/l) and group 3 (0.8 mmol/l)
(p < 0.05). The highest fasting lactate of 2.5 mmol/l was measured
in the treatment group. Lactate production was also found to be
higher in group 2 (data not shown). No effect was seen on these
measures after the 6 weeks of supplementation.
We observed an elevated erythrocyte MCV among the 11
participants on antiviral therapy (mean 109.3 ﬂ, range 95.8–125.2)
compared to the ﬁve controls without HIV (mean 89.3 ﬂ, range 86.6–
92) and the four controls with HIV not on antiviral therapy (mean
88.3 ﬂ, range 85.1–91.4). Perhaps of greatest interest was the
observation of a strong predictive relationship between MCV and
resting lactate (Figure 1) (R2 = 0.548, p < 0.01). As with the lactate
parameters, we did not observe an effect of supplementation on MCV.
4. Discussion
Putative consequences of mitochondrial toxicity associated with
nucleoside analogs – speciﬁcally dideoxynucleosides used for
the treatment of chronic HIV infection – are manifold and rangefrom life-threatening lactic acidosis, anemia, hepatic dysfunction,
peripheral neuropathy, lipodystrophy, nephropathy, decreased bone
density, and, possibly, hypertriglyceridemia.13–22 Although such
toxicities are becoming less common in countries with adequate
resources due to reduced utilization of dideoxynucleoside analogs,
they remain a signiﬁcant concern in resource-constrained settings.23
Indeed, it is in such settings that monitoring for important toxicities
may be most difﬁcult.24 Sternfeld and colleagues were the ﬁrst to
draw our attention to the possibility that macrocytosis may be a
marker of mitochondrial toxicity.8 To our knowledge this is the ﬁrst
published evaluation of resting lactate and macrocytosis. Although
our study is limited by a small sample size, a very strong linear
relationship was observed between MCV and resting lactate,
suggesting that MCV could be used as an indirect marker of
mitochondrial toxicity and could be a red ﬂag for persons at high risk
for the development of the rare but fatal complication of lactic
acidosis.
Interestingly all but one of the 11 study participants on
treatment demonstrated elevated MCV despite not currently being
on AZT. These were highly treatment experienced patients who
had a treatment history of AZT exposure. In our clinical experience
MCV does not always normalize with the substitution of AZT for an
alternate antiviral agent. Despite signiﬁcant variability in mea-
sured lactate in this study, all study participants had a level in the
normal range, in keeping with observations that resting lactate is
not a useful predictor of who will go on to severe lactic acidosis.25
Lactic acidosis represents an acute, rare, and potentially life-
threatening complication of the treatment for HIV, perhaps more
common in resource-constrained regions.26 Two recently pub-
lished papers have suggested strategies to optimize the prevention
of a poor outcome with lactic acidosis among persons on
dideoxynucleoside-based antiviral therapy (Arenas-Pinto 2011
and Matthews 2011). The potential contribution of MCV as an
adjunct for the identiﬁcation of persons at risk of life-threatening
lactic acidosis deserves evaluation.
Finally, many of the toxicities associated with antiviral therapy
present after years of exposure to therapies.27 Although toxicities
such as lipodystrophy are not immediately life-threatening, they
can have a negative impact on mental health28 and metabolic
syndrome.29 It may be that MCV also serves as a predictor of the
development of such longer term yet important toxicities. In our
clinical practice vitamin B12, folate, and thyroid stimulating
hormone levels are rarely found to be contributing to an elevated
MCV, however alcohol does appear to be a signiﬁcant contributor.
It is our opinion that an elevated MCV should not be viewed as a
benign marker of antiviral therapy and deserves investigation and
normalization where possible.
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